NASDAQ:IVA Inventiva (IVA) Stock Forecast, Price & News $4.20 -0.06 (-1.41%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$4.20▼$4.2950-Day Range$3.41▼$4.4452-Week Range$2.22▼$11.75Volume2,118 shsAverage Volume17,876 shsMarket Capitalization$217.35 millionP/E RatioN/ADividend YieldN/APrice Target$19.33 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Inventiva MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside360.3% Upside$19.33 Price TargetShort InterestHealthy0.18% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.02) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector432nd out of 972 stocksPharmaceutical Preparations Industry191st out of 449 stocks 3.5 Analyst's Opinion Consensus RatingInventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.33, Inventiva has a forecasted upside of 360.3% from its current price of $4.20.Amount of Analyst CoverageInventiva has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inventiva has recently decreased by 5.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVA. Previous Next 2.6 News and Social Media Coverage News SentimentInventiva has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Inventiva this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Inventiva to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.46% of the stock of Inventiva is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inventiva are expected to decrease in the coming year, from ($2.02) to ($2.15) per share.Price to Book Value per Share RatioInventiva has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inventiva (NASDAQ:IVA) StockInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More IVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVA Stock News HeadlinesSeptember 28, 2023 | finanznachrichten.deINVENTIVA: Inventiva reports its 2023 first-half financial results and provides a corporate updateSeptember 28, 2023 | finance.yahoo.comInventiva reports its 2023 first-half financial results and provides a corporate updateOctober 1, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 26, 2023 | americanbankingnews.comInventiva (IVA) to Release Earnings on ThursdaySeptember 23, 2023 | americanbankingnews.comInventiva's (IVA) "Buy" Rating Reaffirmed at Roth MkmSeptember 21, 2023 | markets.businessinsider.comInvestors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties EaseSeptember 21, 2023 | markets.businessinsider.comPre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…September 20, 2023 | marketwatch.comInventiva ADRs Rise 9% Following Licensing DealOctober 1, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.September 20, 2023 | finance.yahoo.comInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South KoreaSeptember 20, 2023 | finance.yahoo.comInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South KoreaSeptember 12, 2023 | msn.comIndustry slow to embrace new fatty liver disease nomenclatureAugust 31, 2023 | msn.comurban-gro announces sale of investment for proceeds of $2.3 millionAugust 31, 2023 | msn.comInventiva announced €35.7M funding, eyes future raise to meet obligationsAugust 31, 2023 | finance.yahoo.comInventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificatesAugust 14, 2023 | msn.comDrugmakers still chasing potentially lucrative NASH market, despite setbacksJuly 28, 2023 | finanznachrichten.deINVENTIVA: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business updateJuly 28, 2023 | finance.yahoo.comCorrection: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business updateJuly 28, 2023 | finance.yahoo.comInventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business updateJuly 28, 2023 | finance.yahoo.comCorrection: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business updateJune 24, 2023 | finance.yahoo.comInventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes AssociationJune 16, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $35 Price TargetJune 16, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Inventiva (IVA)June 16, 2023 | markets.businessinsider.comWhere Inventiva Stands With AnalystsJune 14, 2023 | msn.comInventiva jumps 25% after mid-stage data for NASH candidateJune 14, 2023 | markets.businessinsider.comInventiva Rises In Morning TradeJune 14, 2023 | msn.comInventiva Soars on Promising Phase 2 Data in Fatty Liver DiseaseSee More Headlines Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address IVA Company Calendar Today10/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IVA CUSIPN/A CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees109Year Founded2011Price Target and Rating Average Stock Price Forecast$19.33 High Stock Price Forecast$35.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+360.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.63 Current Ratio3.47 Quick Ratio3.45 Sales & Book Value Annual Sales$12.83 million Price / Sales16.94 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book3.68Miscellaneous Outstanding Shares51,750,000Free Float35,192,000Market Cap$217.35 million OptionableNot Optionable Beta0.99 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Frederic Cren (Age 57)Co-Founder, CEO & Chairman Comp: $539.62kDr. Pierre Broqua Ph.D. (Age 61)Co-Founder, Chief Scientific Officer, Deputy CEO & Director Comp: $404.75kMr. Jean Volatier (Age 58)Chief Financial Officer Alice Roudot-Ketelers Pharm.D.Chief Operating OfficerMr. Eric Duranson L.L.M. (Age 49)Gen. Counsel Ms. Nathalie Harroy (Age 56)Head of HR Dr. Irena KonstantinovaHead of Biology & PharmacologyDr. Michael Cooreman (Age 65)Chief Medical Officer Mr. Jean-Paul Dutertre M.D.Head of PharmacovigilanceMore ExecutivesKey CompetitorsKamadaNASDAQ:KMDAY-mAbs TherapeuticsNASDAQ:YMABVerastemNASDAQ:VSTMFoghorn TherapeuticsNASDAQ:FHTXImmuneeringNASDAQ:IMRXView All Competitors IVA Stock - Frequently Asked Questions Should I buy or sell Inventiva stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IVA shares. View IVA analyst ratings or view top-rated stocks. What is Inventiva's stock price forecast for 2023? 5 equities research analysts have issued twelve-month price targets for Inventiva's stock. Their IVA share price forecasts range from $11.00 to $35.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 360.3% from the stock's current price. View analysts price targets for IVA or view top-rated stocks among Wall Street analysts. How have IVA shares performed in 2023? Inventiva's stock was trading at $4.46 at the beginning of the year. Since then, IVA shares have decreased by 5.8% and is now trading at $4.20. View the best growth stocks for 2023 here. Are investors shorting Inventiva? Inventiva saw a decline in short interest in September. As of September 15th, there was short interest totaling 90,900 shares, a decline of 5.6% from the August 31st total of 96,300 shares. Based on an average daily volume of 25,200 shares, the days-to-cover ratio is currently 3.6 days. View Inventiva's Short Interest. When did Inventiva IPO? (IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. What is Inventiva's stock symbol? Inventiva trades on the NASDAQ under the ticker symbol "IVA." How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inventiva's stock price today? One share of IVA stock can currently be purchased for approximately $4.20. How much money does Inventiva make? Inventiva (NASDAQ:IVA) has a market capitalization of $217.35 million and generates $12.83 million in revenue each year. How many employees does Inventiva have? The company employs 109 workers across the globe. How can I contact Inventiva? Inventiva's mailing address is 50 RUE DE DIJON, DAIX I0, 21121. The official website for the company is www.inventivapharma.com. The company can be reached via phone at 33-3-80-44-75-00 or via email at finance@inventivapharma.com. This page (NASDAQ:IVA) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.